Latigo Biotherapeutics IPO
Latigo Biotherapeutics, Inc. · Clinical-stage biopharmaceutical (non-opioid pain medicines)
- Issue price
- $18per share
- Issue size
- $345.6M1,92,00,000 shares
- Face value
- To be announcedper equity share
- Lot size
- To be announcedMin. investment shown once set
- PricingThu, 2026
Information only, not investment advice. This page provides information compiled from official SEC filings for information purposes only. It is not investment advice or a recommendation to buy or sell any security. IPO investments involve risk, including loss of principal; read the prospectus carefully before investing.
Issue details
- Issue type
- Firm commitment, fresh issue
- Fresh issue
- 1,92,00,000 shares ($321.41M)
- Offer for sale
- None
- Total issue
- 1,92,00,000 shares ($345.6M)
- Face value
- —
- Listing at
- Nasdaq
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Valuation
Year ended December 31, 2024- EPS (basic)
- -$90.1
- EPS (diluted)
- -$90.1
- EPS (basic) (Year ended December 31, 2025)
- -$129.23
- EPS (diluted) (Year ended December 31, 2025)
- -$129.23
- EPS (basic) (Three months ended March 31, 2025)
- -$26.8
- EPS (diluted) (Three months ended March 31, 2025)
- -$26.8
- EPS (basic) (Three months ended March 31, 2026)
- -$25.26
- EPS (diluted) (Three months ended March 31, 2026)
- -$25.26
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Financials
Consolidated, restated · ₹ crore| Period ended | 31 Mar 20263 months | 31 Dec 202512 months | 31 Mar 20253 months | 31 Dec 202412 months |
|---|---|---|---|---|
| Profit after tax | -2.30 | -10.92 | -2.10 | -6.12 |
| Net worth | -25.26 | — | — | — |
| Total assets | 5.06 | — | — | — |
12 months vs 12 months: profit after tax −78.4%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
About the company
A clinical-stage biopharmaceutical company developing non-opioid pain medicines that act by inhibiting the Nav1.8 sodium channel. Its lead candidate, LTG-001, is an oral product being studied for moderate to severe acute pain, with further candidates LTG-321 (chronic musculoskeletal pain) and LTG-418 in earlier stages.
- Incorporated
- —
- Industry
- Clinical-stage biopharmaceutical (non-opioid pain medicines)
- Sector
- Healthcare and Pharma
- Website
- latigobio.com
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| Entities affiliated with Westlake BioPartners | 29.90% | 20.90% |
| Entities affiliated with Foresite Capital | 20.50% | 14.30% |
| Entities affiliated with 5AM Ventures | 16.60% | 11.60% |
| Entities affiliated with Blue Owl Healthcare | 7.10% | 5.00% |
| Nima Farzan | 6.20% | 4.40% |
| Deep Track Biotechnology Master Fund, Ltd. | 5.70% | 3.90% |
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Advance LTG-001 through the Phase 3 bunionectomy and open-label safety topline results, the NDA submission and commercial readiness | 12.47 |
| Advance LTG-321 through Phase 2 osteoarthritis proof-of-concept topline results and the start of Phase 3 development | 4.62 |
| Other research and development, including LTG-418, plus working capital and general corporate purposes | Set with price |
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Strengths and risks
Our summary of what the offer document statesSource: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Contacts
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
After listing
Listing price, day-one high and low, and the change from the issue price ($18) appear here after the shares list on Nasdaq.
Work out the gain or loss on allotted shares after charges →
Frequently asked questions
What is the Latigo Biotherapeutics IPO price band?
The final issue price is $18 per share.
Where will Latigo Biotherapeutics shares list?
On Nasdaq.
How will the money raised be used?
$124.7M for , $46.2M for , and the rest for the other stated purposes.
Related IPOs
More healthcare and pharma IPOs
- BlossomHill Therapeutics$16Listed
- Braveheart Bio$18Listed
- Vogenx$13Listed
- Attovia Therapeutics$17Listed
Also managed by Goldman Sachs & Co. LLC
All Goldman Sachs & Co. LLC IPOs →Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.